GlioCART Company
GlioCART is a University of Basel spin-out developing the first CAR-T cell therapy for glioblastoma (GBM), an aggressive brain cancer with median survival of 12-18 months. Its dual-action approach targets tumors directly while secreting a CD47-blocker to reprogram immunosuppressive macrophages in the tumor microenvironment, aiming for better efficacy and reduced side effects than standard care.
Founded Date:
2025-11-01
Headquarters:
Allschwil, Basel-Landschaft, Switzerland, Europe
Industry:
Cell, Gene & Biologics Therapeutics
Super Industry:
Biopharma & Life Science Tools
Investors:
University of Basel, Venture Kick
Ipo Status:
private
City:
Allschwil
Region:
Basel-Landschaft
Country:
Switzerland